Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Articles   |    
Psychiatrists’ Judgments About Antipsychotic Benefit and Risk Outcomes and Formulation in Schizophrenia Treatment
Michael A. Markowitz, M.D., M.S.P.H.; Bennett S. Levitan, M.D., Ph.D.; Ateesha F. Mohamed, M.A.; F. R. Johnson, Ph.D.; John F. P. Bridges, Ph.D.; Larry Alphs, M.D., Ph.D.; Leslie Citrome, M.D., M.P.H.
Psychiatric Services 2014; doi: 10.1176/appi.ps.201300290
View Author and Article Information

When this work was done, Dr. Markowitz was with Janssen Scientific Affairs, LLC, Titusville, New Jersey, where Dr. Alphs is affiliated. Dr. Markowitz is now with the CNS Practice Division, UCB Biosciences, Inc., Raleigh, North Carolina (e-mail: mmarko8@yahoo.com). Dr. Levitan is with Janssen Research and Development, Titusville, New Jersey. When this work was done, Ms. Mohamed was with the Division of Health Preference Assessment, RTI Health Solutions, Research Triangle Park, North Carolina. Ms. Mohamed is now with Bayer Healthcare Pharmaceuticals, Inc., Whippany, New Jersey. Dr. Johnson is with the Center for Clinical and Genetic Economics, Duke University, Durham, North Carolina. Dr. Bridges is with the Bloomberg School of Public Health, Johns Hopkins University, Baltimore. Dr. Citrome is with the Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla.

Copyright © 2014 by the American Psychiatric Association

text A A A
PDF of the full text article.

Objective  The objectives were to quantify psychiatrists’ judgments of the benefits and risks of antipsychotic treatments of patients with schizophrenia and to evaluate how patient adherence history affects these judgments.

Methods  Weights assigned by respondents to risks, benefits, and alternative drug formulations in the treatment of schizophrenia were assessed via a Web-based survey by using a discrete-choice experiment. Respondents in the United States and the United Kingdom chose among alternative scenarios characterized by various levels of improvement in positive symptoms, negative symptoms, social functioning, weight gain, extrapyramidal symptoms (EPS), hyperprolactinemia, and hyperglycemia and by formulation. The effect of patient adherence history on respondents’ judgments was also assessed. Random-parameters logit and bivariate probit models were estimated.

Results  The sample included 394 psychiatrists. Improvement in positive symptoms from “no improvement” to “very much improved” was the most preferred outcome over the range of improvements included and was assigned a relative importance score of 10. Other outcomes, in decreasing order of importance, were improvement in negative symptoms from “no improvement” to “very much improved” (5.2; 95% confidence interval [CI]=4.2–6.2), social functioning from “severe problems” to “mild problems” (4.6, CI=3.8–5.4), no hyperglycemia (1.9, CI=1.5–2.4), <15% weight gain (1.5, CI=.9–2.0), no hyperprolactinemia (1.3, CI=.8–1.6), and no EPS (1.1, CI=.7–1.5). As adherence decreased, formulation became more important than modest efficacy changes and injections were preferred to daily pills (p<.05).

Conclusions  Psychiatrists favored treatments that primarily improve positive symptoms. Choice of formulation became more important as likely adherence declined.

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Related Content
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 20.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 17.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 17.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 29.  >
The American Psychiatric Publishing Textbook of Geriatric Psychiatry, 4th Edition > Chapter 17.  >
Topic Collections
Psychiatric News
Read more at Psychiatric News >>
APA Guidelines
PubMed Articles